Testosterone supplementation did not show consistent benefit for cardiovascular risk , sexual function , mood and behavior , or cognition .
Studies that examined clinical cardiovascular endpoints have not favored testosterone therapy over placebo .
Testosterone is ineffective in treating erectile dysfunction and controlled trials did not show a consistent effect on libido .
Testosterone supplementation consistently increased muscle strength but did not have beneficial effects on physical function .
Most studies on mood-related endpoints found no beneficial effect of testosterone treatment on personality , psychological well-being , or mood .
Testosterone products are recommended by some prescribers in response to a diagnosis or presumption of " low testosterone " ( low-T ) for cardiovascular health , sexual function , muscle weakness or wasting , mood and behavior , and cognition .
Oral testosterone supplementation and chronic low-grade inflammation in elderly men: a 26-week randomized, placebo-controlled trial.
BACKGROUND To determine the effect of oral testosterone supplementation on systemic low- grade inflammation measured by high-sensitive C-reactive protein ( hs-CRP ) in aging men with low testosterone levels . METHODS Two hundred thirty-seven men aged 60 to 80 years with a testosterone level of < 13.7 nmol/L ( below the 50th percentile of the population distribution ) were recruited into a double-blind r and omized placebo-controlled trial . Participants were r and omized to either 4 capsules of 40 mg testosterone undecanoate ( And riol Testocaps , NV Organon , Oss , The Netherl and s ) or placebo daily for 26 weeks . Serum levels of hs-CRP were measured at baseline and at 26 weeks using a near-infrared particle immunoassay of the Synchron LX System ( Beckman Coulter , Fullteron , CA ) . RESULTS The median baseline hs-CRP level was 1.95 mg/L ( 0.30 - 6.43 ) in the testosterone group compared with 1.90 mg/L ( 0.40 - 5.91 ) in the placebo group . After 26 weeks of testosterone supplementation therapy , the 2 intervention groups were not statistically significantly different ( median hs-CRP 2.20 vs 2.00 mg/L , interquartile range 0.40 - 6.54 vs 0.50 - 5.70 , P = .36 ) . In subgroup analysis , neither baseline testosterone level , nor age , nor baseline CRP-level modified the effect of testosterone supplementation on CRP levels . CONCLUSION Oral testosterone undecanoate supplementation , in dosage of 160 mg daily for 26 weeks , does not increase hs-CRP levels in elderly men
Testosterone supplementation did not show consistent benefit for cardiovascular risk , sexual function , mood and behavior , or cognition .
Studies that examined clinical cardiovascular endpoints have not favored testosterone therapy over placebo .
Testosterone is ineffective in treating erectile dysfunction and controlled trials did not show a consistent effect on libido .
Testosterone supplementation consistently increased muscle strength but did not have beneficial effects on physical function .
Most studies on mood-related endpoints found no beneficial effect of testosterone treatment on personality , psychological well-being , or mood .
Testosterone products are recommended by some prescribers in response to a diagnosis or presumption of " low testosterone " ( low-T ) for cardiovascular health , sexual function , muscle weakness or wasting , mood and behavior , and cognition .